leucovorin or levoleucovorin

DRUG2 trials

Sponsors

Fujian Cancer Hospital, Merck Sharp & Dohme LLC

Conditions

Advanced Solid TumorsColorectal CancerMalignant Neoplam

Phase 2

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Fujian Cancer HospitalColorectal Cancer

Start: 2023-11-19End: 2025-03-01Target: 20Updated: 2023-11-15

A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)

Not yet recruitingNCT07793942

Merck Sharp & Dohme LLCMalignant Neoplam, Advanced Solid Tumors

Start: 2026-09-29End: 2030-07-28Target: 480Updated: 2026-08-31

Related Papers

An early on-treatment "coordinated inflammatory niche" plasma signature as a predictor of response in the SYLT026 trial: Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite-stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2026-05-27

Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite stable/proficient mismatch repair metastatic colorectal cancer: Updated survival analysis and safety outcomes from a multicenter, single-arm, phase 2 study (SYLT-026).

Journal of Clinical Oncology2026-01-10

Preliminary safety and efficacy of upfront FOLFOXIRI and bevacizumab with cadonilimab in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer: A multicenter phase II study (SYLT-026).

Journal of Clinical Oncology2025-01-27